DOCSLIB.ORG

2020 Table of Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 Table of Drugs 2020 Table of Drugs Questions regarding coding and billing guidance should be submitted to the insurer in whose jurisdiction a claim would be filed. For private sector health insurance systems, please contact the individual private insurance entity. For Medicaid systems, please contact the Medicaid Agency in the state in which the claim is being filed. For Medicare, contact the Medicare contractor. IA - Intra-arterial administration IV - Intravenous administration IM - Intramuscular administration IT - Intrathecal SC - Subcutaneous administration INH - Administration by inhaled solution VAR - Various routes of administration OTH - Other routes of administration ORAL - Administered orally Intravenous administration includes all methods, such as gravity infusion, injections, and timed pushes. The ‘VAR’ posting denotes various routes of administration and is used for drugs that are commonly administered into joints, cavities, tissues, or topical applications, in addition to other parenteral administrations. Listings posted with ‘OTH’ indicate other administration methods, such as suppositories or catheter injections. A Abatacept 10 mg IV J0129 Abbokinase, see Urokinase Abbokinase, Open Cath, see Urokinase Abciximab 10 mg IV J0130 Abelcet, see Amphotericin B Lipid Complex ABLC, see Amphotericin B AbobotulinumtoxintypeA 5 units IM J0586 Acetaminophen 10 mg IV J0131 Acetazolamide sodium up to 500 mg IM, IV J1120 Acetylcysteine, Injection 100 mg IV J0132 Acetylcysteine, unit dose form per gram INH J7604, J7608 Achromycin, see Tetracycline 1 Actemra, see Tocilizumab ACTH, see Corticotropin Acthar, see Corticotropin Actimmune, see Interferon gamma 1-B Activase, see Alteplase recombinant Acyclovir 5 mg J0133 Adalimumab 20 mg SC J0135 Adcetis, see Brentuximab Vedotin Adenocard, see Adenosine Adenoscan, see Adenosine Adenosine 1 mg IV J0153 Ado-trastuzumab Emtansine 1 mg IV J9354 Adrenalin Chloride, see Adrenalin, epinephrine Adrenalin, epinephrine 0.1 mg SC, IM J0171 Adriamycin PFS, see Doxorubicin HCl Adriamycin RDF, see Doxorubicin HCl Adrucil, see Fluorouracil Aflibercept 1 mg OTH J0178 Agalsidase beta 1 mg IV J0180 Aggrastat, see Tirofiban hydrochloride A-hydroCort, see Hydrocortisone sodium phosphate Akineton, see Biperiden Alatrofloxacin mesylate, Injection 100 mg IV J0200 Albuterol 0.5 mg INH J7620 Albuterol, concentrated form 1 mg INH J7610, J7611 Albuterol, unit dose form 1 mg INH J7609, J7613 Aldesleukin per single use vial IM, IV J9015 Aldomet, see Methyldopate HCl Alefacept 0.5 mg IM, IV J0215 Alferon N, see Interferon alfa-n3 Alglucerase per 10 units IV J0205 Alglucosidase alfa 10 mg IV J0220, J0221 Alkaban-AQ, see Vinblastine sulfate Alkeran, see Melphalan, oral Alpha 1-proteinase inhibitor, human 10 mg IV J0256, J0257 Alphanate J7186 Alprostadil, Injection 1.25 mcg OTH J0270 Alprostadil, urethral suppository OTH J0275 Alteplase recombinant 1 mg IV J2997 Alupent, see Metaproterenol sulfate or Metaproterenol, compounded Amcort, see Triamcinolone diacetate A-methaPred, see Methylprednisolone sodium succinate Amgen, see Interferon alphacon-1 Amifostine 500 mg IV J0207 2 Amikacin sulfate 100 mg J0278 Aminolevalinic acid Hcl unit dose (354 mg) OTH J7308 Aminolevulinic acid Hcl 10% Gel 10 mg OTH J7345 Aminolevulinate 1 gm OTH J7309 Aminophylline/Aminophyllin up to 250 mg IV J0280 Amiodarone HCl 30 mg IV J0282 Amitriptyline HCl up to 20 mg IM J1320 Amobarbital up to 125 mg IM, IV J0300 Amphocin, see Amphotericin B Amphotericin B 50 mg IV J0285 Amphotericin B, lipid complex 10 mg IV J0287-J0289 Ampicillin sodium up to 500 mg IM, IV J0290 Ampicillin sodium/sulbactam sodium per 1.5 gm IM, IV J0295 Amygdalin, see Laetrile, Amygdalin, vitamin B-17 Amytal, see Amobarbital Anabolin LA 100, see Nandrolone decanoate Anadulafungin 1 mg IV J0348 Anascorp, see Centruroides Immune F(ab) Ancef, see Cefazolin sodium Andrest 90-4, see Testosterone enanthate and estradiol valerate Andro-Cyp, see Testosterone cypionate Andro-Cyp 200, see Testosterone cypionate Andro L.A. 200, see Testosterone enanthate Andro-Estro 90-4, see Testosterone enanthate and estradiol valerate Andro/Fem, see Testosterone cypionate and estradiol cypionate Androgyn L.A., see Testosterone enanthate and estradiol valerate Androlone-50, see Nandrolone phenpropionate Androlone-D 100, see Nandrolone decanoate Andronaq-50, see Testosterone suspension Andronaq-LA, see Testosterone cypionate Andronate-200, see Testosterone cypionate Andronate-100, see Testosterone cypionate Andropository 100, see Testosterone enanthate Andryl 200, see Testosterone enanthate Anectine, see Succinylcholine chloride Anergan 25, see Promethazine HCl Anergan 50, see Promethazine HCl Anistreplase 30 units IV J0350 Anti-Inhibitor per IU IV J7198 Antispas, see Dicyclomine HCl Antithrombin III (human) per IU IV J7197 Antithrombin recombinant 50 IU IV J7196 Anzemet, see Dolasetron mesylate Injection A.P.L., see Chorionic gonadotropin Apomorphine Hydrochloride 1 mg SC J0364 Aprepitant 1 mg IV J0185 3 Apresoline, see Hydralazine HCl Aprotinin 10,000 kiu J0365 AquaMEPHYTON, see Vitamin K Aralen, see Chloroquine HCl Aramine, see Metaraminol Aranesp, see Darbepoetin Alfa IV Arbutamine 1 mg J0395 Arcalyst, see Rilanocept Aredia, see Pamidronate disodium Arfonad, see Trimethaphan camsylate 15 mcg INH J7605 Arformoterol tartrate Argatroban (for non-esrd use) 1 mg IV J0883 (for esrd use) 1 mg IV J0884 Aridol, see Mannitol Aripiprazole 0.25 mg IM J0400 Aripiprazole, extended release 1 mg IV J0401 Aripiprazole lauroxil (aristada) 1 mg IV J1944 Aripiprazole lauroxil (aristada initio) 1 mg IV J1943 Aripiprazole lauroxil 1 mg IV J1942 Aristocort Forte, see Triamcinolone diacetate Aristocort Intralesional, see Triamcinolone diacetate Aristospan Intra-Articular, see Triamcinolone hexacetonide Aristospan Intralesional, see Triamcinolone hexacetonide Arrestin, see Trimethobenzamide HCl Arsenic trioxide 1 mg IV J9017 Arzerra, see Ofatumumab Asparaginase 1,000 units IV, IM J9019 10,000 units IV, IM J9020 Astramorph PF, see Morphine sulfate Atezolizumab 10 mg IV J9022 Atgam, see Lymphocyte immune globulin Ativan, see Lorazepam Atropine, concentrated form per mg INH J7635 Atropine, unit dose form per mg INH J7636 Atropine sulfate 0.01 mg IV, IM, SC J0461 Atrovent, see Ipratropium bromide Atryn, see Antithrombin recombinant Aurothioglucose up to 50 mg IM J2910 Autologous cultured chondrocytes implant OTH J7330 Autoplex T, see Hemophilia clotting factors Avelumab 10 mg IV J9023 Avonex, see Interferon beta-1a Azacitidine 1 mg SC J9025 Azathioprine 50 mg ORAL J7500 Azathioprine, parenteral 100 mg IV J7501 Azithromycin, dihydrate 1 gm ORAL Q0144 Azithromycin, injection 500 mg IV J0456 4 B Baclofen 10 mg IT J0475 Baclofen for intrathecal trial 50 mcg OTH J0476 Bactocill, see Oxacillin sodium BAL in oil, see Dimercaprol Banflex, see Orphenadrine citrate Basiliximab 20 mg J0480 BCG live intravesical instillation 1 mg OTH J9030 BCG (Bacillus Calmette and Guérin), live per vial IV J9031 instillation Beclomethasone inhalation solution, unit dose form per mg INH J7622 Belatacept 1 mg IV J0485 Belimumab 10 mg IV J0490 Belinostat 10 mg IV J9032 Bena-D 10, see Diphenhydramine HCl Bena-D 50, see Diphenhydramine HCl Benadryl, see Diphenhydramine HCl Benahist 10, see Diphenhydramine HCl Benahist 50, see Diphenhydramine HCl Ben-Allergin-50, see Diphenhydramine HCl Bendamustine HCl (Treanda) 1 mg IV J9033 Bendamustine HCl (Bendeka) 1 mg IV J9034 Bendamustine HCl (Belrapzo/bendamustine) 1 mg IV J9036 Benefix, see Factor IX, recombinant Benlysta, see Belimumab Benoject-10, see Diphenhydramine HCl Benoject-50, see Diphenhydramine HCl Bentyl, see Dicyclomine Benralizumab 1 mg IV J0517 Benztropine mesylate per 1 mg IM, IV J0515 Berinert, see C-1 esterase inhibitor Berubigen, see Vitamin B-12 cyanocobalamin Beta amyloid per study dose OTH A9599 Betalin 12, see Vitamin B-12 cyanocobalamin Betameth, see Betamethasone sodium phosphate Betamethasone acetate & betamethasone sodium phosphate per 3 mg IM J0702 Betamethasone inhalation solution, unit dose form per mg INH J7624 Betaseron, see Interferon beta-1b Bethanechol chloride up to 5 mg SC J0520 Bevacizumab 10 mg IV J9035 Bevacizumab-awwb 10 mg IV Q5107 Bevacizumab- bvzr (Zirabev) 10 mg IV Q5118 Beziotoxumab 10 mg IV J0565 Bicillin L-A, see Penicillin G benzathine Bicillin C-R 900/300, see Penicillin G procaine and penicillin G benzathine Bicillin C-R, see Penicillin G benzathine and penicillin G procaine 5 BiCNU, see Carmustine Biperiden lactate per 5 mg IM, IV J0190 Bitolterol mesylate,concentrated form per mg INH J7628 Bitolterol mesylate,unit dose form per mg INH J7629 Bivalirudin 1 mg IV J0583 Blenoxane, see Bleomycin sulfate Bleomycin sulfate 15 units IM, IV, SC J9040 Blinatumomab 1 microgram IV J9039 Bortezomib 0.1 mg IV J9041 Bortezomib, not otherwise specified 0.1 mg IV J9044 Botox, see OnabotulinumtoxinA Brentuximab Vedotin 1 mg IV J9042 Brethine, see Terbutaline sulfate or Terbutaline, compounded Bricanyl Subcutaneous, see Terbutaline sulfate Brolucizumab- dbll 1 mg OTH J0179 Brompheniramine maleate per 10 mg IM, SC, IV J0945 Bronkephrine, see Ethylnorepinephrine HCl Bronkosol, see Isoetharine HCl Budesonide inhalation solution, concentrated form0.25 mg INH J7633, J7634 Budesonide inhalation solution, unit dose form 0.5 mg INH J7626, J7627 Buprenorphine Hydrochloride 0.1 mg IM J0592 Buprenorphine/Naloxone 1 mg ORAL J0571 <=3 mg ORAL J0572 >3 mg but <=6 mg ORAL J0573 >6 mg but <=10 mg ORAL J0574 >10 mg ORAL J0575 Burenorphine extended release <=100 mg ORAL Q9991 >100 mg ORAL Q9992 Burosumab-twza
Load more

Recommended publications
  • Treatment of Localized Extranodal NK/T Cell Lymphoma, Nasal Type: a Systematic Review Seok Jin Kim†, Sang Eun Yoon† and Won Seog Kim*
    Kim et al. Journal of Hematology & Oncology (2018) 11:140 https://doi.org/10.1186/s13045-018-0687-0 REVIEW Open Access Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review Seok Jin Kim†, Sang Eun Yoon† and Won Seog Kim* Abstract Extranodal natural killer/T cell lymphoma (ENKTL), nasal type, presents predominantly as a localized disease involving the nasal cavity and adjacent sites, and the treatment of localized nasal ENKTL is a major issue. However, given its rarity, there is no standard therapy based on randomized controlled trials and therefore a lack of consensus on the treatment of localized nasal ENKTL. Currently recommended treatments are based mainly on the results of phase II studies and retrospective analyses. Because the previous outcomes of anthracycline-containing chemotherapy were poor, non- anthracycline-based chemotherapy regimens, including etoposide and L-asparaginase, have been used mainly for patients with localized nasal ENKTL. Radiotherapy also has been used as a main component of treatment because it can produce a rapid response. Accordingly, the combined approach of non-anthracycline-based chemotherapy with radiotherapy is currently recommended as a first-line treatment for localized nasal ENKTL. This review summarizes the different approaches for the use of non-anthracycline-based chemotherapy with radiotherapy including concurrent, sequential, and sandwich chemoradiotherapy, which have been proposed as a first-line treatment for newly diagnosed patients with localized nasal ENKTL. Keywords: Extranodal NK/T cell lymphoma, Chemoradiotherapy, Localized disease Background Treatment for newly diagnosed patients with localized Extranodal natural killer/T cell lymphoma (ENKTL), nasal nasal ENKTL type, is a rare subtype of non-Hodgkin lymphoma [1].
    [Show full text]
  • List of Covered Drugs
    List of Covered Drugs Effective July 1, 2016 INTRODUCTION We are pleased to provide the 2011 Gold Coast Health Plan List of Covered Drugs as a useful reference and informational tool. The GCHP List of Covered Drugs can assist practitioners in selecting clinically appropriate and cost effective products for their patients. The information contained in the GCHP List of Covered Drugs is provided solely for the convenience of medical providers. We do not warrant or assure accuracy of such information nor is it intended to be comprehensive in nature. This List of Covered Drugs is not intended to be a substitute for the knowledge, expertise, skill and judgment of the medical provider in his or her choice of prescription drugs. All the information in this List of Covered Drugs is provided as a reference for drug therapy selection. Specific drug selection for an individual patient rests solely with the prescriber. We assume no responsibility for the actions or omissions of any medical provider based upon reliance, in whole or in part, on the information contained herein. The medical provider should consult the drug manufacturer's product literature or standard references for more detailed information. National guidelines can be found on the National Guideline Clearinghouse site at http://www.guideline.gov PREFACE The GCHP List of Covered Drugs is organized by sections. Each section is divided by therapeutic drug class primarily defined by mechanism of action. Unless exceptions are noted, generally all applicable dosage forms and strengths of the drug cited are included in the GCHP List of Covered Drugs. Generics should be considered the first line of prescribing.
    [Show full text]
  • Role of Thrombin and Thromboxane A2 in Reocclusion Following Coronary
    Proc. Natl. Acad. Sci. USA Vol. 86, pp. 7585-7589, October 1989 Medical Sciences Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator (thrombolytic therapy/coronary thrombosis/platelet activation/reperfusion) DESMOND J. FITZGERALD*I* AND GARRET A. FITZGERALD* Divisions of *Clinical Pharmacology and tCardiology, Vanderbilt University, Nashville, TN 37232 Communicated by Philip Needleman, June 28, 1989 (receivedfor review April 12, 1989) ABSTRACT Reocclusion of the coronary artery occurs against the prothrombinase formed on the platelet surface after thrombolytic therapy of acute myocardlal infarction (13) and the neutralization ofheparin by platelet factor 4 (14) despite routine use of the anticoagulant heparin. However, and thrombospondin (15), proteins released by activated heparin is inhibited by platelet activation, which is greatly platelets. enhanced in this setting. Consequently, it is unclear whether To address the role of thrombin during coronary throm- thrombin induces acute reocclusion. To address this possibility, bolysis, we have examined the effect of a specific thrombin we examined the effect of argatroban {MCI9038, (2R,4R)- inhibitor, argatroban {MCI9038, (2R,4R)-4-methyl-1-[N-(3- 4-methyl-l-[Na-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfo- methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl]-2- nyl)-L-arginyl]-2-piperidinecarboxylic acid}, a specific throm- piperidinecarboxylic acid} on the response to tissue plasmin- bin inhibitor, on the response to tissue-type plasminogen ogen activator (t-PA) in a closed-chest canine model of activator in a dosed-chest canine model of coronary thrombo- coronary thrombosis. MCI9038, an argimine derivative which sis. MCI9038 prolonged the thrombin time and shortened the binds to a hydrophobic pocket close to the active site of time to reperfusion (28 + 2 min vs.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Stroke Prevention in Chronic Kidney Disease Disclosures
    5/18/2020 Controversies: Stroke Prevention in Chronic Kidney Disease Wei Ling Lau, MD FASN FAHA FACP Assistant Professor, Nephrology University of California, Irvine Visiting Fellow at OptumLabsCOPY Disclosures • Prior or current research funding from NIH, AHA, Sanofi, ZS Pharma, and Hub Therapeutics. • Associate Medical Director for home peritoneal dialysis at Fresenius University Dialysis Center of Orange. • Has beenNOT on Fresenius medical advisory board for Velphoro. • No conflicts of interest relevant to the current talk. Controversies: Stroke prevention in CKD Wei Ling Lau, MD DO 1 5/18/2020 Stroke Prevention in CKD • Blood pressure targets • Antiplatelet agents • Statins • Anticoagulation Controversies: Stroke prevention in CKD Wei Ling Lau, MD COPY BP TARGETS Data is limited, as patients with CKD were historically excluded from clinical trials NOT Whelton 2017 ACC/AHA hypertension guidelines [Hypertension 2018] Controversies: Stroke prevention in CKD Wei Ling Lau, MD DO 2 5/18/2020 Systolic Blood Pressure Intervention Trial SPRINT: BP lowering to <120 vs <140 mmHg significantly lowered rate of CVD composite primary outcome; no clear effect on stroke Controversies: Stroke prevention in CKD The SPRINT Research Group. N Engl J Med 2015 p2103 Wei Ling Lau, MD COPY SPRINT subgroup analysis: CKD • Patients with CKD stage 3‐4 (eGFR of 20 to <60) comprised 28% of the SPRINT study population • Intensive BP management seemed to provide the same benefits for reduction in the CVD composite primary outcomeNOT – but did not impact stroke Controversies: Stroke prevention in CKD Cheung 2017 J Am Soc Nephrol p2812 Wei Ling Lau, MD DO 3 5/18/2020 The hazard of incident stroke associated with systolic BP (SBP) and chronic kidney disease (CKD)BP using and an unadjusted stroke model risk: that contained J‐shaped dummy variables association for CKD and BP groups (A) and a fully adjusted model that contained dummy variables for CKD and BP grou..
    [Show full text]
  • Interleukins in Therapeutics
    67 ISSN: 2347 - 7881 Review Article Interleukins in Therapeutics Anjan Khadka Department of Pharmacology, AFMC, Pune, India [email protected] ABSTRACT Interleukins are a subset of a larger group of cellular messenger molecules called cytokines, which are modulators of cellular behaviour. On the basis of their respective cytokine profiles, responses to chemokines, and interactions with other cells, these T-cell subsets can promote different types of inflammatory responses. During the development of allergic disease, effector TH2 cells produce IL-4, IL- 5, IL-9, and IL-32. IL-25, IL- 31, and IL-33 contributes to TH2 responses and inflammation. These cytokines have roles in production of allergen-specific IgE, eosinophilia, and mucus. ILs have role in therapeutics as well as diagnosis and prognosis as biomarker in various conditions. Therapeutic targeting of the IL considered to be rational treatment strategy and promising biologic therapy. Keywords: Interleukins, cytokines, Interleukin Inhibitors, Advances INTRODUCTION meaning ‘hormones’. It was Stanley Cohen in Interleukins are group of cytokines that were 1974 who for the first time introduced the term first seen to be expressed by leucocytes and ‘‘cytokine’’. It includes lymphokines, they interact between cells of the immune monokines, interleukins, and colony stimulating systems. It is termed by Dr. Vern Paetkau factors (CSFs), interferons (IFNs), tumor (University of Victoria) in1979.Interleukins (IL) necrosis factor (TNF) and chemokines. The are able to promote cell growth, differentiation, majority of interleukins are synthesized by and functional activation. The question of how helper CD4 T lymphocytes as well as through diverse cell types communicate with each monocytes, macrophages, and endothelial cells.
    [Show full text]
  • Eptifibatide Is Noninferior to Abciximab: Implications for Clinical Practice
    RESEARCH HIGHLIGHTS ANTIPLATELET THERAPY Eptifibatide is noninferior to abciximab: implications for clinical practice he glycoprotein IIb/IIIa (GPIIb/ randomized, open, parallel-group January 2004 and December 2007, IIIa) inhibitors eptifibatide and comparison of eptifibatide and abciximab and eptifibatide was used in 2,355 Tabciximab have comparable efficacy in 427 patients presenting within 12 h such procedures over this time frame. and safety in patients with ST-segment of STEMI onset and who underwent During the 1-year follow-up period, elevation myocardial infarction (STEMI) primary PCI. Enrolled patients were from no significant difference was reported undergoing primary percutaneous 22 centers in France and Germany. The for the incidence of death (8.0% and coronary intervention (PCI). These two study drugs were administered in 7.6%), myocardial infarction (9.0% and findings, from a randomized trial and a combination with background therapy 8.4%), or bleeding (2.7% and 3.2%) registry study, are reported in two papers comprising clopidogrel, aspirin, and between abciximab and eptifibatide, published in the Journal of the American heparin or enoxaparin. This study used respectively. Multivariable analysis College of Cardiology (JACC). the surrogate primary end point of showed that eptifibatide was noninferior Platelet aggregation and thrombus complete electrocardiographic ST-segment to abciximab for the prevention of death formation can be inhibited by blocking resolution (STR) 60 min after completion or myocardial infarction (odds ratio 0.94, the GPIIb/IIIa receptor on the platelet of PCI. 95% CI 0.82–1.09). membrane, thereby preventing the binding In the intention-to-treat analysis, These findings “fuel an already much of fibrinogen.
    [Show full text]
  • Challenges and Approaches for the Development of Safer Immunomodulatory Biologics
    REVIEWS Challenges and approaches for the development of safer immunomodulatory biologics Jean G. Sathish1*, Swaminathan Sethu1*, Marie-Christine Bielsky2, Lolke de Haan3, Neil S. French1, Karthik Govindappa1, James Green4, Christopher E. M. Griffiths5, Stephen Holgate6, David Jones2, Ian Kimber7, Jonathan Moggs8, Dean J. Naisbitt1, Munir Pirmohamed1, Gabriele Reichmann9, Jennifer Sims10, Meena Subramanyam11, Marque D. Todd12, Jan Willem Van Der Laan13, Richard J. Weaver14 and B. Kevin Park1 Abstract | Immunomodulatory biologics, which render their therapeutic effects by modulating or harnessing immune responses, have proven their therapeutic utility in several complex conditions including cancer and autoimmune diseases. However, unwanted adverse reactions — including serious infections, malignancy, cytokine release syndrome, anaphylaxis and hypersensitivity as well as immunogenicity — pose a challenge to the development of new (and safer) immunomodulatory biologics. In this article, we assess the safety issues associated with immunomodulatory biologics and discuss the current approaches for predicting and mitigating adverse reactions associated with their use. We also outline how these approaches can inform the development of safer immunomodulatory biologics. Immunomodulatory Biologics currently represent more than 30% of licensed The high specificity of the interactions of immu- biologics pharmaceutical products and have expanded the thera- nomodulatory biologics with their relevant immune Biotechnology-derived peutic options available
    [Show full text]
  • Ciera L. Patzke, Alison P. Duffy, Vu H. Duong, Firas El Chaer 4, James A
    Journal of Clinical Medicine Article Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia Ciera L. Patzke 1, Alison P. Duffy 1,2, Vu H. Duong 1,3, Firas El Chaer 4, James A. Trovato 2, Maria R. Baer 1,3, Søren M. Bentzen 1,3 and Ashkan Emadi 1,3,* 1 Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 21201, USA; [email protected] (C.L.P.); aduff[email protected] (A.P.D.); [email protected] (V.H.D.); [email protected] (M.R.B.); [email protected] (S.M.B.) 2 School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA; [email protected] 3 School of Medicine, University of Maryland, Baltimore, MD 21201, USA 4 School of Medicine, University of Virginia, Charlottesville, VA 22908, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-410-328-2596 Received: 10 January 2020; Accepted: 13 February 2020; Published: 16 February 2020 Abstract: Currently, no standard of care exists for the treatment of relapsed or refractory acute myeloid leukemia (AML). We present our institutional experience with using either CLAG-M or HAM-pegA, a novel regimen that includes pegaspargase. This is a retrospective comparison of 34 patients receiving CLAG-M and 10 receiving HAM-pegA as first salvage cytotoxic chemotherapy in the relapsed or refractory setting. Composite complete response rates were 47.1% for CLAG-M and 90% for HAM-pegA (p = 0.027).
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Use of Fluorescence to Guide Resection Or Biopsy of Primary Brain Tumors and Brain Metastases
    Neurosurg Focus 36 (2):E10, 2014 ©AANS, 2014 Use of fluorescence to guide resection or biopsy of primary brain tumors and brain metastases *SERGE MARBACHER, M.D., M.SC.,1,5 ELISABETH KLINGER, M.D.,2 LUCIA SCHWYZER, M.D.,1,5 INGEBORG FISCHER, M.D.,3 EDIN NEVZATI, M.D.,1 MICHAEL DIEPERS, M.D.,2,5 ULRICH ROELCKE, M.D.,4,5 ALI-REZA FATHI, M.D.,1,5 DANIEL COLUCCIA, M.D.,1,5 AND JAVIER FANDINO, M.D.1,5 Departments of 1Neurosurgery, 2Neuroradiology, 3Pathology, and 4Neurology, and 5Brain Tumor Center, Kantonsspital Aarau, Aarau, Switzerland Object. The accurate discrimination between tumor and normal tissue is crucial for determining how much to resect and therefore for the clinical outcome of patients with brain tumors. In recent years, guidance with 5-aminolev- ulinic acid (5-ALA)–induced intraoperative fluorescence has proven to be a useful surgical adjunct for gross-total resection of high-grade gliomas. The clinical utility of 5-ALA in resection of brain tumors other than glioblastomas has not yet been established. The authors assessed the frequency of positive 5-ALA fluorescence in a cohort of pa- tients with primary brain tumors and metastases. Methods. The authors conducted a single-center retrospective analysis of 531 patients with intracranial tumors treated by 5-ALA–guided resection or biopsy. They analyzed patient characteristics, preoperative and postoperative liver function test results, intraoperative tumor fluorescence, and histological data. They also screened discharge summaries for clinical adverse effects resulting from the administration of 5-ALA. Intraoperative qualitative 5-ALA fluorescence (none, mild, moderate, and strong) was documented by the surgeon and dichotomized into negative and positive fluorescence.
    [Show full text]
  • Deliverable 5.A Interim Report on the Study Results APPENDIX 2
    Deliverable 5.a Interim report on the study results APPENDIX 2: Algorithms used to identify study variables for service contract EMA/2011/38/CN ‐ PIOGLITAZONE November 28th 2012 D5.a Interim report on the study results (Appendix 2) for Service Contract EMA/2011/38/CN PIOGLITAZONE Author(s): Vera Ehrenstein (AUH‐AS) APPENDIX 2. ALGORITHMS USED TO IDENTIFY STUDY VARIABLES Algorithms for AU Database DISEASE/CONDITION ICD-8 CODE (1977-1993) ICD-10 CODE (1994-) Diabetes type 2 250.00; 250.06; 250.07; 250.09 E11.0; E11.1; E11.9 Cancer of bladder 188 C67 Haematuria N/A R31 Haematuria, unspecified B18, K70.0–K70.3, K70.9, K71, K73, Mild hepatic impairment 571, 573.01, 573.04 K74, K76.0 Moderate to severe hepatic 070.00, 070.02, 070.04, 070.06, B15.0, B16.0, B16.2, B19.0, K70.4, impairment 070.08, 573.00, 456.00–456.09 K72, K76.6, I85 Acute myocardial infarction 410 I21-I23 Acute coronary syndrome 410, 413 I20-I24 Ischemic heart disease 410-414 I20-I25 427.09, 427.10, 427.11, 427.19, Congestive heart failure I50, I11.0, I13.0,I13.2 428.99, 782.49; Acute renal failure N/A N17 Diabetic coma N/A E10.0, E11.0, E12.0,E13.0, E14.0 Diabetic acidosis N/A E10.1, E11.1, E12.1,E13.1, E14.1 F10.1-F10.9, G31.2, G62.1, G72.1, Alcoholism 291, 303, 577.10, 571.09, 571.10 I42.6, K29.2, K86.0, Z72.1 Obesity 277.99 E65-E66 D5.a Interim report on the study results (Appendix 2) for Service Contract EMA/2011/38/CN PIOGLITAZONE Author(s): Vera Ehrenstein (AUH‐AS) Algorithms for defining acute events in Denmark, ICD-10 code Event ICD-10 code I21.x, I23.x http://apps.who.int/classifications/icd10/browse/2010/en#/I21
    [Show full text]